FDA Sets July Meeting to Reconsider Peptide Compounding Limits Backed by RFK Jr.

The Food and Drug Administration has formally scheduled an advisory committee meeting in July 2026 to weigh easing restrictions on more than seven injectable peptides, including influencer‑favored BPC‑157, after public advocacy from Robert F. Kennedy Jr. The agency says it will ask outside advisers whether those specific peptides should be added to the list of substances that pharmacies may legally compound and will, in the meantime, remove them from its restrictive “do not compound” list. Kennedy previewed the policy shift in a Joe Rogan interview, describing himself as a “big fan” of peptides, and the timing has drawn attention because the FDA’s compounding advisory panel currently has vacant seats that could be filled before the meeting.

The proposed reconsideration follows earlier agency action: under the prior administration the FDA had added nearly 20 peptides to its 2023 “do not compound” list after advisers and staff concluded they posed significant safety risks. Those concerns are rooted in a history of serious compounding problems — between 2001 and 2019 there were 73 reported compounding errors or potential errors tied to more than 1,562 adverse events and at least 1,079 deaths — and the agency has documented severe adverse events, including a death linked to intravenous ipamorelin. The market for such products has also ballooned, with e‑commerce listings for problematic peptide products growing roughly 276% over five years, and user reports for BPC‑157 note side effects from widespread itching to intense anxiety alongside regulator warnings about impurities and incomplete safety data.

Public reaction has been mixed and fast: investors and wellness companies responded with immediate market moves — one social‑media account noted a more than 20% jump in Hims & Hers shares — while proponents frame the move as expanding regulated access and innovation in longevity and “peptidology.” Critics and some former agency officials warn the change risks undercutting the drug‑approval system; former FDA official Peter Lurie called the prospect of compounding untested peptides a “profound threat,” and outlets such as ProPublica have highlighted that the shift effectively reverses the 2023 safety‑based restrictions. Earlier mainstream coverage emphasized safety-based bans and agency caution; newer reporting, driven in part by PBS’s notice about the July meeting and investigative outlets flagging the reversal, frames the story around a political and policy shift toward easing access and the potential for regulatory capture as vacancies on advisory panels could be filled before advisers weigh in.